Variable | No.(%) | Median OS (months) | P | Median PFS (months) | P |
---|---|---|---|---|---|
Gender | Â | Â | 0.002 | Â | 0.131 |
 Male | 78 (57.78) | 15.39 |  | 7.86 |  |
 Female | 57 (42.22) | 22.49 |  | 8.48 |  |
LANCL2 gene status | Â | Â | 0.054 | Â | 0.177 |
 Amplification | 33 (24.44) | 15.02 |  | 5.85 |  |
 No alteration | 102 (75.56) | 18.08 |  | 8.48 |  |
EGFR gene status | Â | Â | 0.128 | Â | 0.795 |
 Amplification | 56 (41.48) | 17.49 |  | 8.12 |  |
 No alteration | 79 (58.52) | 17.79 |  | 7.63 |  |
LANCL2 and EGFR genes status | Â | Â | 0.054 | Â | 0.177 |
 Co-amplification | 33 (24.44) | 15.02 |  | 5.85 |  |
 No alteration | 102 (75.56) | 18.08 |  | 8.48 |  |